GeNO is a biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases. We are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl™ drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Our technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.
We are currently developing two next-generation drug products: GeNOsyl™ Acute DS for use in the hospital setting, and GeNOsyl™ Chronic DS, a lightweight system that can be worn by patients with chronic diseases for use outside of the hospital setting.
CAUTION: The GeNO nitric oxide delivery systems are investigational and limited by federal law to investigational use only.